- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05855083
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Pediatric Patients (28 Days to ≤ 18 Years of Age.) With High-Risk Hematopoietic Stem Cell Transplant Thrombotic Microangiopathy
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a Phase 2, uncontrolled, single-dosing regimen study in pediatric patients from 28 days to less than 18 years of age with high risk HSCT-TMA. At least 4 patients will be required from each of 3 age cohorts:
28 days to <2 years of age, 2 years to <12 years of age, and 12 years to <18 years of age.
Treatment will be for 8 weeks and patients will be followed for up to 52 weeks.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Expanded Access
Contacts and Locations
Study Contact
- Name: Omeros Clinical Trial Information
- Phone Number: 206-676-5000
- Email: ctinfo@omeros.com
Study Locations
-
-
-
Halle, Germany
- Not yet recruiting
- Omeros Investigational Site
-
Hanover, Germany
- Not yet recruiting
- Omeros Investigational Site
-
-
-
-
-
Haifa, Israel
- Not yet recruiting
- Omeros Investigational Site
-
Jerusalem, Israel
- Not yet recruiting
- Omeros Investigational Site
-
Ramat Gan, Israel
- Not yet recruiting
- Omeros Investigational Site
-
Tel Aviv, Israel
- Not yet recruiting
- Omeros Investigational Site
-
-
-
-
-
Utrecht, Netherlands
- Not yet recruiting
- Omeros Investigational Site
-
-
-
-
-
Pamplona, Spain
- Recruiting
- Omeros Investigational Site
-
-
-
-
California
-
San Diego, California, United States, 92024
- Recruiting
- Omeros Investigational Site
-
-
Florida
-
Gainesville, Florida, United States, 32608
- Not yet recruiting
- Omeros Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Not yet recruiting
- Omeros Investigational Site
-
-
Missouri
-
Saint Louis, Missouri, United States, 63104
- Recruiting
- Omeros Investigational Site
-
-
New York
-
New York, New York, United States, 10065
- Not yet recruiting
- Omeros Investigational Site
-
Valhalla, New York, United States, 10595
- Recruiting
- Omeros Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Not yet recruiting
- Omeros Investigational Site
-
-
Washington
-
Seattle, Washington, United States, 98105
- Not yet recruiting
- Omeros Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age at least 28 days and less than 18 years prior to informed consent (Visit 0).
- Have informed consent from at least one parent or legal guardian as required by local law and regulation. Patient informed consent will be required if the patient has reached the local legal age of majority.
- Assent from patients as required by local law and regulation.
- Have received an allogeneic hematopoietic stem cell transplant for the treatment of benign or malignant disease.
Have a diagnosis of HSCT-TMA defined as meeting both of the following criteria:
- Platelet count < 50,000/mL or a decrease in platelet count > 50% from the highest value obtained following transplant.
- Evidence of microangiopathic hemolysis (presence of schistocytes, serum lactate dehydrogenase [LDH] > upper limit of normal ([ULN], or haptoglobin < lower limit of normal [LLN])
Have at least one of the following HSCT-TMA high-risk criteria:
- HSCT-TMA persistence > 2 weeks following modification of calcineurin inhibitors or sirolimus OR
Have evidence of high-risk HSCT-TMA defined as at least one of the following:
- Spot protein/creatinine ratio > 2 mg/mg
- Serum creatinine > 1.5 x the creatinine level prior to TMA development
- Biopsy-proven gastrointestinal TMA
- TMA-related neurological abnormality
- Pericardial or pleural effusion without alternative explanation
- Pulmonary hypertension without alternative explanation
- Have Grade III or Grade IV graft-versus-host disease (GVHD) or, in the opinion of the Investigator, risk for development of Grade III or Grade IV GVHD if immunosuppression were to be modified
- Have elevated serum C5b-9 (> 244 ng/mL)
- If sexually active and of childbearing potential (for female pediatric patients, defined as starting at onset of menses), must agree to practice a highly effective method of birth control throughout study drug treatment and for at least 12 weeks after the last dose of study drug, such method of birth control defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence (abstinence is acceptable when it is in line with the patient's preferred and usual lifestyle and is defined as complete abstinence of sexual intercourse, not periodic abstinence or withdrawal), or vasectomized partner.
- Male patients must be willing to avoid fathering children for at least 12 weeks following the last dose of study medication.
Exclusion Criteria:
All treatments for HSCT-TMA are allowed except eculizumab, ravulizumab, and defibrotide within 3 months prior to informed consent, unless failure of therapy can be documented.
a. Patients may not be on eculizumab, ravulizumab, or defibrotide for any indication at screening.
- Have Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS). Test results obtained within 28 days prior to informed consent may be used.
- Have ADAMTS13 activity < 10%. Test results obtained within 28 days prior to informed consent may be used.
- Have a severe, uncontrolled systemic bacterial or fungal infection requiring antimicrobial therapy, or a severe uncontrolled viral infection (as determined by the investigator); prophylactic antimicrobial therapy administered as standard of care is allowed.
- Have malignant hypertension (blood pressure [BP] > 99th percentile plus 5 mmHg with bilateral hemorrhages or "cotton-wool" exudates on fundoscopic examination).
- Due to conditions other than HSCT-TMA, have a poor prognosis with a life expectancy of less than 3 months in the opinion of the Investigator.
- If pregnant or lactating.
- Have received treatment with an investigational drug or device within 4 weeks of entering study.
- Have abnormal liver function tests defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times ULN within 28 days prior to informed consent.
- Have a positive test by antigen or polymerase chain reaction (PCR) for human immunodeficiency virus (HIV), if negative within 28 days prior to informed consent, the test does not need to be repeated.
- Patient or one or more of the patient's parents or legal guardians are is an employee or an immediate family member of Omeros, the Clinical Research Organization (CRO), an Investigator, or a study staff member.
- Have a known hypersensitivity to any constituent of the product.
- Presence of any condition that the Investigator believes would put the patient at risk.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Narsoplimab single arm-treatment
Narsoplimab 4 mg/kg
|
Treatment with narsoplimab 4 mg/kg will be administered
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
100-day survival rate following high-risk HSCT-TMA diagnosis.
Time Frame: 100 days
|
Percentage of patients alive at 100 days following the diagnosis of high-risk HSCT-TMA
|
100 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-emergent adverse events assessed by CTCAE v5.0
Time Frame: 52 weeks
|
Number and percentage of patients with treatment-emergent adverse events will be summarized by MedDRA system organ class and preferred term
|
52 weeks
|
Percentage of patients meeting protocol definition of clinical response
Time Frame: 52 weeks
|
A responder is defined as a patient with HSCT-TMA who demonstrates improvement in laboratory TMA markers (platelet count and LDH) and clinical benefit (either improvement in organ function or reduction in transfusion burden)
|
52 weeks
|
52 week survival rate following high-risk HSCT-TMA diagnosis
Time Frame: 52 weeks
|
Percentage of patients alive at 52 weeks following the diagnosis of high-risk HSCT-TMA
|
52 weeks
|
Overall survival following the diagnosis of high-risk HSCT-TMA
Time Frame: 52 weeks
|
Median overall survival (days) following the diagnosis of high-risk HSCT-TMA by Kaplan-Meier estimate
|
52 weeks
|
Pharmacokinetics (PK) of multiple-dose administration of OMS721
Time Frame: 52 weeks
|
PK parameters including maximum concentration and minimum (trough) concentration
|
52 weeks
|
Presence of anti-drug antibody (ADA)
Time Frame: 52 weeks
|
Number and percentage of patient with at least one ADA positive sample
|
52 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OMS721-HCT-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombotic Microangiopathies
-
Peking University Third HospitalNot yet recruitingPregnancy-related Thrombotic Microangiopathies
-
The First Affiliated Hospital of Soochow UniversityRecruiting
-
University of California, San FranciscoCompleted
-
University of CologneUnknownThrombotic Microangiopathies
-
University Hospital, MontpellierRecruitingThrombotic Micro-angiopathyFrance
-
Omeros CorporationImpatients N.V. trading as myTomorrowsAvailableHematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)
-
Hospices Civils de LyonRecruitingHematopoietic Stem Cell Transplantation-Associated Thrombotic MicroangiopathyFrance
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingThrombotic Microangiopathies
-
AKARI TherapeuticsRecruitingThrombotic MicroangiopathiesUnited States, United Kingdom, Poland
-
The First Affiliated Hospital of Soochow UniversityCompletedHematologic Diseases | Thrombotic MicroangiopathiesChina
Clinical Trials on Biological: narsoplimab
-
Omeros CorporationUnknownLupus Nephritis | IgAN | C3 Glomerulopathy | MNUnited States, Hong Kong
-
Omeros CorporationImpatients N.V. trading as myTomorrowsAvailableHematopoietic Stem Cell Transplant Associated Thrombotic Microangiopathy (HSCT-TMA)
-
Istituto Ortopedico RizzoliCompleted
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingBrain Tumor | Brain Lesion (General)France
-
AstraZenecaActive, not recruiting
-
Assistance Publique - Hôpitaux de ParisNot yet recruiting
-
Centre Hospitalier Universitaire de NīmesCompleted
-
Centre Hospitalier Sud FrancilienCompletedFungal Infection | Bronchopulmonary Dysplasia | Extreme PrematurityFrance
-
University Hospital, ToursRecruitingAcute Lymphoid Leukemia | Acute Myeloid Leukemia in ChildrenFrance
-
Imagine InstituteReference center for rare diseases (Rare Gynecologic Diseases)RecruitingMayer Rokitansky Kuster Hauser SyndromeFrance